MY176465A - Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines - Google Patents

Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines

Info

Publication number
MY176465A
MY176465A MYPI2016701546A MYPI2016701546A MY176465A MY 176465 A MY176465 A MY 176465A MY PI2016701546 A MYPI2016701546 A MY PI2016701546A MY PI2016701546 A MYPI2016701546 A MY PI2016701546A MY 176465 A MY176465 A MY 176465A
Authority
MY
Malaysia
Prior art keywords
deoxy
difluorotetrahydrouridines
synthetic route
intermediates
synthesizing
Prior art date
Application number
MYPI2016701546A
Other languages
English (en)
Inventor
Hyeong-Wook Choi
Steven Mathieu
Frank Fang
Bryan Matthew Lewis
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MY176465A publication Critical patent/MY176465A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201Oxygen-containing compounds
    • B01J31/0209Esters of carboxylic or carbonic acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0237Amines
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0244Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2016701546A 2013-10-29 2014-10-29 Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines MY176465A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361896703P 2013-10-29 2013-10-29

Publications (1)

Publication Number Publication Date
MY176465A true MY176465A (en) 2020-08-11

Family

ID=51982743

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016701546A MY176465A (en) 2013-10-29 2014-10-29 Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines

Country Status (19)

Country Link
US (3) US9834576B2 (enExample)
EP (1) EP3063164B1 (enExample)
JP (1) JP6427567B2 (enExample)
KR (1) KR102272773B1 (enExample)
CN (1) CN105683209B (enExample)
AU (1) AU2014342402B2 (enExample)
BR (1) BR112016008855B1 (enExample)
CA (1) CA2926734C (enExample)
ES (1) ES2712877T3 (enExample)
IL (1) IL244849B (enExample)
MX (1) MX363205B (enExample)
MY (1) MY176465A (enExample)
NZ (1) NZ718607A (enExample)
PH (1) PH12016500683B1 (enExample)
RU (1) RU2681939C2 (enExample)
SA (1) SA516371019B1 (enExample)
SG (1) SG11201602614XA (enExample)
WO (1) WO2015066162A1 (enExample)
ZA (1) ZA201602315B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926734C (en) 2013-10-29 2022-03-15 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
EP4041743A4 (en) * 2019-10-08 2024-03-13 Otsuka Pharmaceutical Co., Ltd. HIGH PURITY 2'-DEOXY-2',2'-DIFLUORTETRAHYDROURIDINE AND METHOD FOR THE PRODUCTION THEREOF
PT4069254T (pt) 2020-02-25 2024-10-10 Otsuka Pharma Co Ltd Formas sólidas de dosagem oral compreendendo decitabina e cedazuridina
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
CN113402573B (zh) * 2020-07-31 2023-06-20 集美大学 一种鞣质类化合物及其提取方法和应用
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
TWI821074B (zh) * 2021-12-25 2023-11-01 台灣神隆股份有限公司 製備希達路里定(cedazuridine)的方法
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
EP0876149A4 (en) 1995-12-22 2001-09-26 Univ East Carolina METHOD FOR TREATING DISORDERS CHARACTERIZED BY A CYTIDINE DEAMINASE OR DESOXYCYTIDINE DEAMINASE
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
CN102241720B (zh) 2000-11-29 2014-01-29 三井化学株式会社 L-核酸衍生物及其合成方法
FI112640B (fi) 2000-12-22 2003-12-31 Kone Corp Hissin turvalaite
KR101108407B1 (ko) * 2006-06-21 2012-01-30 일라이 릴리 앤드 캄파니 젬시타빈 아미드 전구약물의 결정 형태, 그의 조성물 및 용도
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2926734C (en) 2013-10-29 2022-03-15 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Also Published As

Publication number Publication date
PH12016500683A1 (en) 2016-05-30
US10526362B2 (en) 2020-01-07
EP3063164A1 (en) 2016-09-07
RU2681939C2 (ru) 2019-03-14
BR112016008855A2 (enExample) 2017-08-01
US11028119B2 (en) 2021-06-08
AU2014342402B2 (en) 2018-11-01
CA2926734C (en) 2022-03-15
AU2014342402A1 (en) 2016-04-21
KR20160083021A (ko) 2016-07-11
US20160237107A1 (en) 2016-08-18
EP3063164B1 (en) 2018-12-05
ZA201602315B (en) 2019-07-31
RU2016115523A3 (enExample) 2018-06-05
JP6427567B2 (ja) 2018-11-21
JP2017500281A (ja) 2017-01-05
ES2712877T3 (es) 2019-05-16
US20200123189A1 (en) 2020-04-23
IL244849B (en) 2019-10-31
KR102272773B1 (ko) 2021-07-02
CN105683209A (zh) 2016-06-15
US20180072768A1 (en) 2018-03-15
HK1223627A1 (en) 2017-08-04
SA516371019B1 (ar) 2018-01-23
MX2016005596A (es) 2016-12-09
CN105683209B (zh) 2019-03-08
WO2015066162A1 (en) 2015-05-07
US9834576B2 (en) 2017-12-05
NZ718607A (en) 2019-10-25
RU2016115523A (ru) 2017-12-04
BR112016008855B1 (pt) 2023-01-17
PH12016500683B1 (en) 2020-02-14
CA2926734A1 (en) 2015-05-07
IL244849A0 (en) 2016-05-31
SG11201602614XA (en) 2016-05-30
MX363205B (es) 2019-03-13

Similar Documents

Publication Publication Date Title
MY176465A (en) Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines
PH12016501763A1 (en) Multispecific antibodies
MY184733A (en) Pyrimidine fgfr4 inhibitors
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
UY34817A (es) Tienopirimidinas
ZA201703510B (en) Antibodies, uses & methods
IN2013MU00848A (enExample)
AU2014224814A8 (en) Novel halogen-substituted compounds
IN2014DN06738A (enExample)
NZ720106A (en) A process for the preparation of regadenoson
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
IL244393A0 (en) A new derivative of 6,2-diaminopyrimidine
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MX2017000318A (es) Derivados del acido abscisico sustituido en 3'.
MY171860A (en) Method for purifying a crude pnpnh compound
IN2013MU04030A (enExample)
MX382969B (es) Método para producir halocetonas.
IN2013CH05395A (enExample)
IN2013MU01524A (enExample)
IN2013CH05394A (enExample)
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6